February 16, 2024
2 mins read

India rejects EU’s data exclusivity demand  

Commerce Secretary Sunil Barthwal said that there is no free trade agreement (FTA) in which India will go against the generic drug industry. ..reports Asian Lite News

India will continue to protect the interests of its generic drug firms and has rejected European Free Trade Association (EFTA) nations’ demand to keep “data exclusivity” as a part of the intellectual property (IP) chapter under a proposed bilateral trade deal, a top government official said on Thursday.

Commerce Secretary Sunil Barthwal said that there is no free trade agreement (FTA) in which India will go against the generic drug industry. EFTA comprises Iceland, Switzerland, Norway and Liechtenstein.

“They want there should be data exclusivity, but we rejected their demand. We are with our generic industry. There is no fear for the Indian generic industry (from this agreement). In fact, it is our very important objective to see that the generic drug industry flourishes,” Barthway told reporters.

For over a decade, India has been against the inclusion of data exclusivity provisions in FTAs to protect the interest of the domestic generic drug industry. Through data exclusivity, technical data generated by innovator companies get protection, which stops their competitors from getting cheaper versions of the medicine for a certain time period or till the innovator companies have ‘exclusivity rights’.

Even in the past, India’s discussions on IPR have been a contentious issue in FTA negotiations with countries such as Japan, the United Kingdom (UK) and trade blocs such as the European Union (EU).

According to international medical humanitarian organisation Doctors Without Borders/ Médecins Sans Frontières (MSF), Public Eye, and Delhi Network of Positive People, the draft leaked chapter on IP has provisions on data exclusivity, which can hamper the production of cheap, lifesaving generic medicines from India.

“This would result in generic manufacturers either needing to wait out the exclusivity period or repeat expensive clinical trials. In cases where a new medicine is patented, data exclusivity could block compulsory licences that may be granted to generic manufacturers to produce medicines at lower prices,” said a statement from MSF on Wednesday.

ALSO READ: US, UK carry out fresh strikes in Yemen

Previous Story

Indian, Chinese firms helping Russia may face EU curbs

Next Story

‘India Unfazed by England’s Bazball Talk’

Latest from -Top News

Trump unhappy with deadly strikes on Kyiv 

The president said he is “putting a lot of pressure” on both sides to end the war in Ukraine, following the deadliest attacks Kyiv has seen since last July  President Donald Trump

Macron: ‘We Stand with India’

Macron said that France will stand together with its allies and would continue the fight against terrorism wherever necessary….reports Asian Lite News French President Emmanuel Macron on Friday spoke to Prime Minister

Pakistan Slams IWT Move as ‘Act of War’

Islamabad also said that India’s decision to suspend the Indus Waters Treaty (IWT) will be considered as an “act of war”…reports Asian Lite News The high-level emergency meeting of Pakistan’s National Security

Modi: We’ll Hunt Them Down

The Prime Minister thanked nations that extended support to India in the aftermath of the terror attack…reports Asian Lite News In his first address after the horrific terror attack in Pahalgam, Jammu
Go toTop

Don't Miss

India invites Australian varsities to set up campuses

The two Ministers agreed to expand the cooperation in learning,

India’s commerce secretary in UK for FTA talks

During the visit scheduled for July 17 and 18, the